Literature DB >> 33860626

In utero and peripartum antiretroviral exposure as predictor of cognition in 6- to 10-year-old HIV-exposed Ugandan children - a prospective cohort study.

A E Ezeamama1, S K Zalwango2, A Sikorskii1, R Tuke1, P M Musoke3,4, B Giordani5, M J Boivin6,7.   

Abstract

OBJECTIVES: To quantify association between in utero/peripartum antiretroviral (IPA) exposure and cognition, i.e. executive function (EF) and socioemotional adjustment (SEA), in school-aged Ugandan children who were perinatally HIV-infected (CPHIV, n = 100) and children who were HIV-exposed but uninfected (CHEU, n = 101).
METHODS: Children were enrolled at age 6-10 years and followed for 12 months from March 2017 to December 2018. Caregiver-reported child EF and SEA competencies were assessed using validated questionnaires at baseline, 6 and 12 months. IPA type - combination antiretroviral therapy (cART), intrapartum single-dose nevirapine ± zidovudine (sdNVP ± ZDV), nevirapine + zidovudine + lamivudine (sdNVP + ZDV + 3TC) - or no IPA (reference) was verified via medical records. IPA-related standardized mean differences (SMDs) with corresponding 95% confidence intervals (CIs) in cognitive competencies were estimated from regression models with adjustment for caregiver sociodemographic and contextual factors. Models were fitted separately for CPHIV and CHEU.
RESULTS: Among CPHIV children, cART (SMD = -0.82, 95% CI: -1.37 to -0.28) and sdNVP ± ZDV (SMD = -0.41, 95% CI: -0.81 to -0.00) vs. no IPA predicted lower executive dysfunction over 12 months. Intrapartum sdNVP + ZDV + 3TC vs. no IPA predicted executive dysfunction (SMD = 0.80, 95% CI: 0.30-1.31), SEA problems (SMD = 0.63-0.76, 95% CI: 0.00-1.24) and lower adaptive skills (SMD = -0.36, 95% CI: -0.75-0.02) over 12 months among CHEU. Further adjustment for contextual factors attenuated associations, although most remained of moderate clinical importance (|SMD| > 0.33).
CONCLUSIONS: Among CPHIV children, cART and sdNVP ± ZDV IPA exposure predicted, on average, lower executive dysfunction 6-10 years later. However, peripartum sdNVP + ZDV + 3TC predicted executive and SEA dysfunction among CHEU 6-10 years later. These data underscore the need for more research into long-term effects of in utero ART to inform development of appropriate interventions so as to mitigate cognitive sequelae.
© 2021 British HIV Association.

Entities:  

Keywords:  HIV-exposed children; cognitive function; executive function; in utero ART; maternal ART; socioemotional adjustment

Mesh:

Substances:

Year:  2021        PMID: 33860626      PMCID: PMC8585519          DOI: 10.1111/hiv.13094

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  57 in total

1.  Social origins of executive function development.

Authors:  Stephanie M Carlson
Journal:  New Dir Child Adolesc Dev       Date:  2009

2.  Appendix II. Youth Risk Behavior Surveillance System Questionnaire.

Authors: 
Journal:  Public Health Rep       Date:  1993       Impact factor: 2.792

Review 3.  Intraclass correlations: uses in assessing rater reliability.

Authors:  P E Shrout; J L Fleiss
Journal:  Psychol Bull       Date:  1979-03       Impact factor: 17.737

4.  Emotion regulation and the quality of social interaction: does the ability to evaluate emotional situations and identify effective responses matter?

Authors:  Paulo N Lopes; John B Nezlek; Natalio Extremera; Janine Hertel; Pablo Fernández-Berrocal; Astrid Schütz; Peter Salovey
Journal:  J Pers       Date:  2011-04

5.  Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children.

Authors:  Micah Piske; Matthew A Budd; Annie Q Qiu; Evelyn J Maan; Laura J Sauvé; John C Forbes; Ariane Alimenti; Patricia Janssen; Hélène C F Côté
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 6.  Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?.

Authors:  Jonathan Underwood; Kevin R Robertson; Alan Winston
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

7.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Authors:  J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

8.  SOCIAL: an integrative framework for the development of social skills.

Authors:  Miriam H Beauchamp; Vicki Anderson
Journal:  Psychol Bull       Date:  2010-01       Impact factor: 17.737

Review 9.  Antiretroviral Treatment in HIV-1-Positive Mothers: Neurological Implications in Virus-Free Children.

Authors:  Antonio Victor Campos Coelho; Paola Maura Tricarico; Fulvio Celsi; Sergio Crovella
Journal:  Int J Mol Sci       Date:  2017-02-15       Impact factor: 5.923

10.  Perinatal HIV Infection or Exposure Is Associated With Low N-Acetylaspartate and Glutamate in Basal Ganglia at Age 9 but Not 7 Years.

Authors:  Frances C Robertson; Martha J Holmes; Mark F Cotton; Els Dobbels; Francesca Little; Barbara Laughton; André J W van der Kouwe; Ernesta M Meintjes
Journal:  Front Hum Neurosci       Date:  2018-05-07       Impact factor: 3.169

View more
  2 in total

1.  Developmental Disorder Probability Scores at 6-18 Years Old in Relation to In-Utero/Peripartum Antiretroviral Drug Exposure among Ugandan Children.

Authors:  Jorem Emmillian Awadu; Alla Sikorskii; Sarah Zalwango; Audrey Coventry; Bruno Giordani; Amara E Ezeamama
Journal:  Int J Environ Res Public Health       Date:  2022-03-21       Impact factor: 3.390

Review 2.  Central Nervous System Impact of Perinatally Acquired HIV in Adolescents and Adults: an Update.

Authors:  Sharon L Nichols
Journal:  Curr HIV/AIDS Rep       Date:  2022-02-02       Impact factor: 5.071

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.